<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Incredible_Magic_Formula_Of_Your_diglyceride</id>
		<title>Incredible Magic Formula Of Your diglyceride - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Incredible_Magic_Formula_Of_Your_diglyceride"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Incredible_Magic_Formula_Of_Your_diglyceride&amp;action=history"/>
		<updated>2026-06-17T09:36:00Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Incredible_Magic_Formula_Of_Your_diglyceride&amp;diff=125139&amp;oldid=prev</id>
		<title>Animal13neck: Створена сторінка: 1%, 56.1%, and 49.6% reductions, respectively, P?[http://www.selleckchem.com/products/iox1.html IOX1 research buy] P? outcomes in a double-blind, placebo-contro...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Incredible_Magic_Formula_Of_Your_diglyceride&amp;diff=125139&amp;oldid=prev"/>
				<updated>2016-12-27T17:07:00Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 1%, 56.1%, and 49.6% reductions, respectively, P?[http://www.selleckchem.com/products/iox1.html IOX1 research buy] P? outcomes in a double-blind, placebo-contro...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;1%, 56.1%, and 49.6% reductions, respectively, P?[http://www.selleckchem.com/products/iox1.html IOX1 research buy] P? outcomes in a double-blind, placebo-controlled study of extended-release (ER) hydromorphone among opioid-tolerant patients with chronic low back pain. Methods:? Four hundred fifty-nine (N?=?459) patients participated in the titration/conversion phase of a multicenter study, of which 268 were randomized [http://www.selleckchem.com/products/i-bet-762.html check details] to receive once-daily hydromorphone or placebo. All patients completed the Hospital Anxiety and Depression Scale (HADS) at baseline and were divided evenly into Low (N?=?157), Moderate (N?=?155), and High (N?=?147) negative affect groups based on their scores. Group differences in numerical pain intensity measures at home and in the clinic, Roland�CMorris Disability ratings, and measures of symptoms from the Subjective Opiate Withdrawal Scale (SOWS) throughout the trial were analyzed. Results:? Two hundred sixty-eight of the initial 459 subjects who entered the 2 to 4-week titration/conversion phase (pretreatment) were successfully randomized to either placebo or ER hydromorphone; a total of 110 patients then completed this double-bflind [http://en.wikipedia.org/wiki/Diglyceride diglyceride] phase of the study. Those in the Moderate and High negative affect groups tended to drop out more often during the titration/conversion phase because of the adverse effects or lack of efficacy of their prescribed opioid than those in the Low negative mood group (P?&lt;/div&gt;</summary>
		<author><name>Animal13neck</name></author>	</entry>

	</feed>